AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02350075 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implants installation
Description: Dental implants installation is a procedure to insert dental implants into alveolar bone.
Study NCT02350075 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Osteotome Sinus floor elevation
Description: Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
Study NCT02317601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Single dose Intravenous
Study NCT02317601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Study NCT04566952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
Study NCT04566952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be treated with a total daily dose of 450 or 300mg.
Study NCT04242576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right Left Judgement
Description: It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
Study NCT04242576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Videos of cervical movements.
Study NCT04242576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Evidence based exercises for the neck.
Study NCT00820807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: oral consumption in beverage
Study NCT00820807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral consumption in beverage
Study NCT01489267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
Study NCT01665872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Group Therapy
Description: CBT Group
Study NCT01665872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Group Therapy
Description: CBT Group
Study NCT02143960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VelaShape III
Description: Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
Study NCT02143960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolSculpt
Description: Noninvasive Cryolipolysis
Study NCT04199546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chewing and swallowing rehabilitation
Description: A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
Study NCT02108834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
Study NCT02108834 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
Study NCT04331925 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Anxiety and depression screening
Description: At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
Study NCT04331925 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Journaling
Description: Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
Study NCT04331925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journaling
Description: Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
Study NCT04071171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVVH with Phoxilium® in the first 48h after randomization
Description: After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study NCT04071171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVVH with Biphozyl® in the first 48h after randomization
Description: After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study NCT04071171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study NCT04071171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study NCT04390997 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical Periodontal Treatment
Description: Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
Study NCT02473224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.2 Challenge
Description: GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
Study NCT02473224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration
Study NCT03511300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting Instructions
Description: In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)
Study NCT03511300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Instructions
Description: Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
Study NCT03511300 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Instructions
Description: Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
Study NCT02167724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bucco-dental examination
Study NCT02167724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02167724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and social questionnaire
Study NCT01999348 — intervention group
Intervention type: DRUG
Intervention: Fixed Combination Bimatoprost and Timolol
Description: Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
Study NCT01464814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic plus fish oil capsule
Description: Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
Study NCT01464814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil capsule
Description: Fish oil capsule, T.I.D., for seven (7) days
Study NCT03436147 — intervention group
Intervention type: OTHER
Intervention: POP-Q
Description: Pelvic Organ Prolapse Quantification
Study NCT03782844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple CPAP+Conventional fixed CPAP
Description: Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
Study NCT03782844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple CPAP + Auto CPAP
Description: Patients used simple CPAP and Auto CPAP during overnight polysomnography.
Study NCT04283357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Short Foot Exercises
Study NCT04283357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Exercise with virtual reality
Study NCT02620735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fit bit Device
Description: Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
Study NCT02620735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Only
Description: 12 week exercise program
Study NCT02620735 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: 12 week exercise program
Study NCT02601430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOLD-MRI
Description: A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
Study NCT00780767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANGIOJET RHEOLYTIC THROMBECTOMY
Description: The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
Study NCT01434628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
Study NCT00740441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1411
Description: AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
Study NCT02788032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EnergieShake oral supplement
Description: The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
Study NCT02929160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Description: Percutaneous nephrostomy tube insertion under radiological guidance
Study NCT02929160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde ureteric JJ stent
Description: Retrograde ureteric JJ stent insertion using cystoscopy
Study NCT00606411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate or Placebo
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
Study NCT00606411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate or Placebo
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
Study NCT02620735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connected Wellness HealthCoach Software
Description: Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
Study NCT02620735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: 10 over the phone health coaching sessions.
Study NCT04955496 — intervention group
Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery
Description: ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
Study NCT01057862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Targeted dosage of 50mg PO daily
Study NCT01057862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills daily PO
Study NCT03759028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study NCT03759028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study NCT03759028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study NCT03759028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study NCT00156013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLOFARABINE
Description: 4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
Study NCT04287439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
Study NCT04287439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
Study NCT04287439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention matched control
Description: Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Description: One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium
Description: One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
Study NCT04692831 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zr-ss-pertuzumab PET/CT
Description: Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03244384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-0954E
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.
Study NCT00628537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION stimulation
Description: BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises.
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to losartan potassium
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.
Study NCT01302691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to amlodipine besylate
Description: One capsule, containing placebo, orally, once daily, for 8 weeks.
Study NCT02177812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
Study NCT02177812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing